Company news
Quantum Biopharma Ltd. Subordinate Voting Shares Class B (CSE:QNTM) news
Quantum Biopharma Ltd. Subordinate Voting Shares Class B news releases on 6ix. Latest, Oct 6, 2026: Quantum BioPharma Signs Contract with Thermo Fisher…
View Quantum Biopharma Ltd. Subordinate Voting Shares Class B →
Press releases & updates
Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
October 6, 2026
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
September 30, 2026
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
September 24, 2026
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
September 17, 2026
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
September 15, 2026
NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating 'Rare Moment' in MS Research
September 14, 2026
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
September 11, 2026
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
September 9, 2026
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
September 8, 2026
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
September 1, 2026
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
August 14, 2026
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
August 10, 2026
Quantum BioPharma Announces Closing of Debt Settlement
July 30, 2026
Quantum BioPharma Announces Intention to Settle Debt
July 20, 2026
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis
June 26, 2026
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
June 25, 2026
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
June 23, 2026
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
June 2, 2026
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
May 18, 2026
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
May 7, 2026
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
April 22, 2026
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
April 2, 2026
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
April 1, 2026
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
March 30, 2026
Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status
March 27, 2026
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis
March 26, 2026
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd
March 23, 2026
Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering
March 20, 2026
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM
February 18, 2026
Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors
February 17, 2026
Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors
February 17, 2026
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
February 5, 2026
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM
February 3, 2026
Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors
February 2, 2026
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM
January 29, 2026
QNTM DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026
January 12, 2026
QUANTUM BIOPHARMA DEADLINE FOR LEADERSHIP is February 23, 2026 in a Securities Fraud Lawsuit - Contact Kaplan Fox & Kilsheimer LLP
January 10, 2026
Deadline to Lead in Securities Class Action Against Quantum Biopharma Ltd. (QNTM) is February 23, 2026 - Contact Kaplan Fox
January 9, 2026
QNTM CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026
January 8, 2026
QNTM DEADLINE: Investors of Quantum Biopharma Ltd. (QNTM) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 23, 2026
January 7, 2026
Kaplan Fox Alerts Quantum Biopharma Ltd. (QNTM) Investors to a Securities Class Action Lawsuit - Deadline is February 23, 2026
January 6, 2026
QUANTUM BIOPHARMA Investors are Encouraged to Contact Kaplan Fox Regarding the Securities Class Action Lawsuit
January 5, 2026
Kaplan Fox Reminds Quantum Biopharma Ltd. (QNTM) Investors of a Securities Class Action Lawsuit
January 3, 2026
Kaplan Fox Encourages Investors of Quantum Biopharma Ltd. (QNTM) to Contact the Firm Regarding the Securities Class Action Lawsuit
January 2, 2026
Kaplan Fox Alerts Investors of Quantum Biopharma Ltd. (QNTM) to a Securities Class Action Lawsuit
January 1, 2026
Kaplan Fox Alerts Investors to Securities Class Action on Behalf of Quantum Biopharma Ltd. (QNTM) Shareholders
December 31, 2025
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)
December 23, 2025